Agenus Inc. (NASDAQ:AGEN) has a beta value of 1.28 and has seen 1.81 million shares traded in the recent trading session. The company, currently valued at $1.23B, closed the recent trade at $5.07 per share which meant it lost -$0.02 on the day or -0.39% during that session. The AGEN stock price is -33.93% off its 52-week high price of $6.79 and 50.69% above the 52-week low of $2.50. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.8 million shares traded. The 3-month trading volume is 3.58 million shares.
The consensus among analysts is that Agenus Inc. (AGEN) is a Buy stock at the moment, with a recommendation rating of 1.30. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is $0.46.
Agenus Inc. (NASDAQ:AGEN) trade information
Sporting -0.39% in the red today, the stock has traded in the red over the last five days, with the highest price hit on Monday, 10/18/21 when the AGEN stock price touched $5.07 or saw a rise of 11.83%. Year-to-date, Agenus Inc. shares have moved 60.06%, while the 5-day performance has seen it change -9.91%. Over the past 30 days, the shares of Agenus Inc. (NASDAQ:AGEN) have changed -12.69%. Short interest in the company has seen 21.27 million shares shorted with days to cover at 5.02.
Wall Street analysts have a consensus price target for the stock at $10.00, which means that the shares’ value could jump 49.3% from the levels at last check today. The projected low price target is $8.00 while the price target rests at a high of $12.00. In that case, then, we find that the latest price level in today’s session is -136.69% off the targeted high while a plunge would see the stock gain -57.79% from the levels at last check today.
Agenus Inc. (AGEN) estimates and forecasts
Figures show that Agenus Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained 90.28% over the past 6 months, with this year growth rate of 73.33%, compared to 6.80% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 264.30% and 45.00% for the next quarter. Revenue growth from the last financial year stood is estimated to be 198.60%.
3 analysts offering their estimates for the company have set an average revenue estimate of $183.11 million for the current quarter. 3 have an estimated revenue figure of $57.72 million for the next quarter concluding in Dec 2021. Year-ago sales stood $14 million and $31.27 million respectively for this quarter and the next, and analysts expect sales will grow by 1,207.90% for the current quarter and 84.60% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 1.40% over the past 5 years.
Agenus Inc. is expected to release its next earnings report on May 06 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Agenus Inc. (NASDAQ:AGEN)’s Major holders
Insiders own 12.80% of the company shares, while shares held by institutions stand at 50.46% with a share float percentage of 57.87%. Investors are also buoyed by the number of investors in a company, with Agenus Inc. having a total of 205 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 16.15 million shares worth more than $88.64 million. As of Jun 29, 2021, Blackrock Inc. held 6.93% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 13.9 million shares as of Jun 29, 2021. The firm’s total holdings are worth over $76.33 million and represent 5.96% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of Sep 29, 2021, the former fund manager holds about 3.60% shares in the company for having 8.4 million shares of worth $44.1 million while later fund manager owns 5.32 million shares of worth $29.23 million as of Jun 29, 2021, which makes it owner of about 2.28% of company’s outstanding stock.